Peer-reviewed veterinary case report
Fenoldopam treatment for kidney injury in dogs with heatstroke
By Segev, Gilad et al.·Published in Journal of veterinary internal medicine·2018·Department of Small Animals Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of fenoldopam on kidney function parameters and its therapeutic efficacy in the management of acute kidney injury in dogs with heatstroke.
- Species:
- dog
Plain-English summary
A group of 40 dogs suffering from heatstroke were treated with either fenoldopam, a medication aimed at improving kidney function, or a placebo. Unfortunately, the study found that fenoldopam did not significantly improve kidney function or urine production compared to the placebo. Out of the dogs, 55% were diagnosed with acute kidney injury (AKI), and the overall survival rate was similar between both treatment groups. This means that fenoldopam did not provide a clear benefit for dogs with kidney issues related to heatstroke.
People also search for: dog heatstroke treatment · fenoldopam for dogs · acute kidney injury in dogs · dog kidney function improvement · heatstroke symptoms in dogs
Abstract
BACKGROUND: Acute kidney injury (AKI) is common in dogs, but evidence of efficacy of its treatment is lacking. OBJECTIVE: To evaluate the efficacy of fenoldopam in the management of AKI. ANIMALS: Forty dogs with naturally occurring heatstroke. METHODS: Dogs were prospectively enrolled and divided into treatment and the placebo groups (fenoldopam, constant rate infusion [CRI] of 0.1 µg/kg/min or saline, respectively). Urine production (UP) was measured using a closed system. Urinary clearances were performed at 4, 12, and 24 hours after presentation to estimate the effect of fenoldopam on UP, glomerular filtration rate (GFR) and sodium fractional excretion (NaFE). RESULTS: At presentation, severity of heatstroke, based on a previously developed scoring system, was similar between the study groups, but was significantly worse in nonsurvivors compared with survivors. Fenoldopam administration was not associated with hypotension. Overt AKI was diagnosed, based on the International Renal Interest Society guidelines in 22/40 (55%) of the dogs. Overall, 14/40 dogs (35%) died, with no significant (P = .507) mortality rate difference between the fenoldopam (6/20 dogs; 30%) and placebo (8/20; 40%) groups. The proportion of dogs with AKI did not differ between the fenoldopam and the placebo groups (9/20; 45% versus 13/20; 65%, respectively; P = .204). There were no differences in UP, GFR, and NaFE between the fenoldopam and the placebo groups. CONCLUSION AND CLINICAL IMPORTANCE: Fenoldopam CRI at 0.1 µg/kg/min did not have a clinically relevant effect on kidney function parameters in dogs with severe heatstroke-associated AKI.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29575360/